• 1
    Park YH, Lee SJ, Cho EY, et al. Clinical relevance of TNM staging system according to breast subtypes. Ann Oncol. 2011;22:15541560.
  • 2
    van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347:19992009.
  • 3
    Goldhirsch A, Wood WC, Coates AS, et al; Panel members. Strategies for subtypes–dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22:17361747.
  • 4
    Cady B. Lymph node metastases. Indicators, but not governors of survival. Arch Surg. 1984;119:1067.
  • 5
    Kerlikowske K, Grady D, Rubin SM, et al. Efficacy of screening mammography. A meta-analysis. JAMA. 1995;273:149154.
  • 6
    Lin PP, Allison DC, Wainstock J, et al. Impact of axillary lymph node dissection on the therapy of breast cancer patients. J Clin Oncol. 1993;11:15361544.
  • 7
    Ivens D, Hoe AL, Podd TJ, et al. Assessment of morbidity from complete axillary dissection. Br J Cancer. 1992;66:136138.
  • 8
    Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg. 1994;220:391398; discussion 398-401.
  • 9
    Krag D, Weaver D, Ashilaga T, et al. The sentinel node in breast cancer–a multicenter validation study. N Engl J Med. 1998;339:941946.
  • 10
    Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305:569575.
  • 11
    Menard S, Bufalino R, Rilke F, et al. Prognosis based on primary breast carcinoma instead of pathological nodal status. Br J Cancer. 1994;70:709712.
  • 12
    Greco M, Agresti R, Cascinelli N, et al. Breast cancer patients treated without axillary surgery: clinical implication and biological analysis. Ann Surg. 2000;232:17.
  • 13
    Fisher B, Redmond C, Fisher ER, et al. Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med. 1985;312:674681.
  • 14
    Veronesi U, Salvadori B, Luini A, et al. Conservative treatment of early breast cancer. Long-term results of 1232 cases treated with quadrantectomy, axillary dissection, and radiotherapy. Ann Surg. 1990;211:250259.
  • 15
    Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histologic grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19:403410.
  • 16
    Zafrani B, Aubriot MH, Mouret E, et al. High sensitivity and specificity of immunohistochemistry for the detection of hormone receptors in breast carcinoma: comparison with biochemical determination in a prospective study of 793 cases. Histopathology. 2000;37:563545.
  • 17
    Martignone S, Pellegrini R, Villa E, et al. Characterization of two monoclonal antibodies directed against the 67 kDa high affinity laminin receptor and application for the study of breast carcinoma progression. Clin Exp Metastasis. 1992;10:379386.
  • 18
    Lachin JM, Foulkes MA. Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry: losses to follow-up, noncompliance, and stratification. Biometrics. 1986;42:507519.
  • 19
    Marubini E, Mariani L, Salvadori B, et al. Results of a breast-cancer-surgery trial compared with observational data from routine practice. Lancet. 1996;347:10001003.
  • 20
    Piaggio G, Elbourne DR, Altman DG, et al. Reporting of noninferiority and equivalence randomized trials. JAMA. 2006;295:11521160.
  • 21
    Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:11411154.
  • 22
    Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496509.
  • 23
    Piccart-Gebhart MJ, Sotiriou C. Adjuvant chemotherapy-yes or no? Prognostic markers in early breast cancer. Ann Oncol. 2007;18(suppl 12):xii2xii7.
  • 24
    Martelli G, Boracchi P, Ardoino I, et al. Axillary dissection versus no axillary dissection in older patients with T1N0 breast cancer: 15-year results of a randomized controlled trial. Ann Surg. 2012;256:920924.
  • 25
    International Breast Cancer Study Group, Rudenstam CM, Zahrieh D, et al. Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 10-93. J Clin Oncol. 2006;24:337344.
  • 26
    Martelli G, Miceli R, Daidone MG, et al. Axillary dissection versus no axillary dissection in elderly patients with breast cancer and no palpable axillary nodes: results after 15 years of follow-up. Ann Surg Oncol. 2011;18:125133.
  • 27
    Howat JM, Barnes DM. Oestrogen receptor status and management of breast cancer. Lancet. 1981;1:1317.
  • 28
    Sainsbury JR, Farndon JR, Sherbet GV, Harris AL. Epidermal-growth-factor receptors and oestrogen receptors in human breast cancer. Lancet. 1985;1:364366.
  • 29
    Seshadri R, Firgaira FA, Horsfall DJ, McCaul K, Setlur V, Kitchen P. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. J Clin Oncol. 1993;11:19361942.
  • 30
    Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med. 2009;360:790800.